Reportedly, collaborating with Corgenix and Tulane in the contract are The Scripps Research Institute, the University of California at San Diego, Boston University, the Broad Institute, Harvard University, Autoimmune Technologies, Vybion and various partners in West Africa.
James Robinson, professor of pediatrics at the Tulane University School of Medicine and principle investigator of the program, said: “This study will result in a fundamental understanding of the mechanisms of antibody detection and antibody mediated neutralization of Lassa virus. This research has implications for the next generation of antibody based therapeutics against viral hemorrhagic fevers.”
Douglass Simpson, president and CEO of Corgenix, said: “We are extremely pleased to be part of this expanded collaboration and to have received the NIH contract. Building on the previous two grants for development of state-of-the-art diagnostic tests on multiple delivery platforms, this new contract will enable Tulane and the other collaborators to probe deeper into the mechanisms of the virus, which can ultimately lead to prevention of the disease.”